Executive team

Commercial Research Management

DIGICORE is open to working with any researcher, be they academic or industrial. On this page you can find how industrial researchers can access DIGICORE, and the sorts of research we do.

Commercial Research Team

The commercial research manager appointed by the board is Dr Piers Mahon, European Data and Evidence Network lead at IQVIA. Piers has a wide ranging interest in translational research, including time in Silicon Valley in RWE methods development at Cancer Commons.
He and his team at IQVIA supported one of the prototype networks for DIGICORE, the Oncology Evidence Network, inside IQVIA. This network of 7 centres has spearheaded the development of many of the research methods we will use in DIGICORE, and specialises in both the delivery of broad cohort research (such as natural history and outcomes research) as well as narrow cohorts with work underway in multiple molecular subtypes of NSCLC and other cancers, on both a commercial fee for service basis and for academic research.

How to work with us

To propose conventional commercial real world evidence projects on a fee for service basis to DIGICORE please contact your real world account manager at IQVIA who will triage your request appropriately.

Commercial Research Team

Examples of the sorts of innovation we are interested in co-developing

  • Reusable infrastructures for patient finding in external comparators to accelerate such programmes and reduce waste in the patient matching process. These are especially useful to portfolio owners with large heam or NSCLC franchises. We are also interested in “research on research” to validate these methods and understand how best to use them, working in partnership with regulators and payers
  • Development of ethical and compliant off-label observatories, especially for precision medicines, so that we can better understand the clinical benefits and risks of such practice
  • Developing methods for the Mendelian randomisation not of germline but of somatic mutations to study their impact on clinical response to cancer treatment in real world data. Such programmes will transform large panel and liquid biopsy test evidence and help support their broader introduction for the benefits of many patients
  • Federating biobanks and coordinating sample capture so that there are large multi-centre cohorts of sample not just for discovery research, but the far tougher requirements of translational research and molecular diagnostic development.
    An example use of such programmes would be to better understand the mechanism of non-response or hyper-progression to immune-oncology treatment and validate tests to identify such patients.
  • The validation of digital therapeutics and remote patient monitoring technology using Real world data and novel trial methods to deal with confounders such as patient motivation bias. We anticipate these methods will become the reimbursement norm in Europe
  • The design, development, and regulatory acceptance of pragmatic, fully digital, platform trials especially asynchronous designs. We have a programme in Cachexia in design given that features of this disease (and it current evidence base) make it well suited to validating such novel methods before their extension to new agents of uncertain safety
  • Developing the cost effective digital tooling for the above, appropriate for an international federated network looking to operate at “regulatory grade”. This will include everything from pragmatic common data models, data capture innovation, pragmatic outcome development and validation, novel NLP and PRO development and validation

Please note that as a public private partnership we will not consider proposals for the development of proprietary or exclusive research networks.

For more information: info@digicore-cancer.eu